Cellectar Biosciences (CLRB) to Release Quarterly Earnings on Thursday

Cellectar Biosciences (NASDAQ:CLRB) is expected to be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Cellectar Biosciences to post earnings of ($0.38) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Cellectar Biosciences Trading Down 0.8 %

Shares of CLRB opened at $0.31 on Wednesday. Cellectar Biosciences has a 12-month low of $0.22 and a 12-month high of $4.17. The firm has a 50-day moving average price of $0.29 and a 200 day moving average price of $1.19. The firm has a market capitalization of $14.41 million, a P/E ratio of -0.18 and a beta of 0.96.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cellectar Biosciences stock. Bank of America Corp DE grew its holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 25.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 206,783 shares of the biopharmaceutical company’s stock after purchasing an additional 41,704 shares during the quarter. Bank of America Corp DE owned 0.45% of Cellectar Biosciences worth $62,000 at the end of the most recent reporting period. Institutional investors own 16.41% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Oppenheimer reaffirmed a “market perform” rating on shares of Cellectar Biosciences in a research note on Wednesday, December 11th. LADENBURG THALM/SH SH assumed coverage on shares of Cellectar Biosciences in a research note on Thursday, December 5th. They set a “buy” rating and a $13.00 target price for the company. Finally, StockNews.com assumed coverage on shares of Cellectar Biosciences in a research note on Monday. They set a “sell” rating for the company.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.